Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840641 | 0.89 | PPIA (0.74) | PPIAHTTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL15840660 | 0.86 | PPIA (0.62) | PPIAHTTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL15840666 | 0.85 | LMNA (0.63) | PPIAHTTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL15840714 | 0.83 | HTT (0.67) | HTTLMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL15840723 | 0.83 | FFAR4 (0.67) | PPIAHTTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL12904023 | 0.82 | PPIA (0.70) | PPIAHTTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL15840816 | 0.81 | PPIA (0.57) | PPIAHTTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL13470109 | 0.79 | ALDH1A1 (0.64) | PPIAHTTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13453969 | 0.79 | ALDH1A1 (0.60) | PPIAHTTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13470355 | 0.79 | ALDH1A1 (0.62) | PPIAHTTLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | PPIA 1884/4885HTT 1693/4885LMNA 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.